Serglycin expression in CD2+ and CD14+ cells from patients with various rheumatic diseases

The objective of the study was to look at the in vivo expression of serglycin in cells taken from patients with an inflammatory disease. The mRNA expression of the small proteoglycan serglycin was investigated in macrophages/monocytes and T-cells derived from the synovial fluid and blood of six pati...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of rheumatology 2001-01, Vol.30 (3), p.164-166
Main Authors: OMTVEDT, Lone A, KOLSET, Svein Olav, THOEN, Jørn, FØRRE, Øystein, GILL, Mark R
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
CD2 Antigens - analysis
Diseases of the osteoarticular system
Female
Humans
Inflammatory joint diseases
Lipopolysaccharide Receptors - analysis
Lymphocyte Subsets - metabolism
Male
Medical sciences
Middle Aged
Proteoglycans - blood
Proteoglycans - metabolism
Rheumatic Diseases - blood
Rheumatic Diseases - metabolism
Serglycin Proteoglycans Rheumatic Diseases Inflammation
Synovial Fluid - metabolism
Vesicular Transport Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of the study was to look at the in vivo expression of serglycin in cells taken from patients with an inflammatory disease. The mRNA expression of the small proteoglycan serglycin was investigated in macrophages/monocytes and T-cells derived from the synovial fluid and blood of six patients with various rheumatic diseases and from the blood of two control subjects. Our results demonstrate higher levels of expression in CD14+ cells taken from patients with chronic inflammatory diseases than in control subjects. This suggests that serglycin may play a role during the inflammatory process.
ISSN:0300-9742
1502-7732
DOI:10.1080/030097401300162941